Form 4: Zimmer Biomet CFO Reports Routine Stock Transactions

Zimmer Biomet's CFO, Suketu Upadhyay, reported the vesting and tax-related disposition of restricted stock units, alongside the acquisition of new RSUs.

Summary

• CFO Suketu Upadhyay acquired 5,445 shares of common stock through the vesting of restricted stock units on February 20, 2026.
• 2,446 shares were withheld by Zimmer Biomet Holdings, Inc. at a price of $98.62 per share to cover tax withholding obligations related to the RSU vesting on February 20, 2026.
• Following these transactions, the CFO beneficially owns 57,753 shares of common stock directly.
• A new grant of 21,701 Restricted Stock Units (RSUs) was awarded to the CFO on February 20, 2026.
• These new RSUs will vest annually over three years, with one-third vesting each year, commencing February 20, 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices and continued alignment of the CFO's interests with the company's long-term performance through new RSU grants.

Positives

• The CFO received a new grant of 21,701 Restricted Stock Units, indicating continued long-term incentive and alignment with shareholder interests.
• The vesting of 5,445 RSUs demonstrates the realization of previously granted equity compensation.

Negatives

• 2,446 shares were disposed of to cover tax obligations, reducing the direct shareholding, which is a standard but dilutive event.

Future Outlook

The new RSU grant to the CFO vests over three years starting February 20, 2027, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through restricted stock units, is a common practice in the medical device industry to align executive incentives with long-term company performance and shareholder value. This filing reflects a routine compensation event for a key executive.

Comparison to Industry Standards

• Equity compensation packages for senior executives in the medical device sector, such as those at Medtronic or Stryker, often include significant RSU grants that vest over multiple years, similar to the structure seen here for Zimmer Biomet's CFO.
• The vesting schedule and tax withholding practices are standard for such awards across the industry.

Related Party Transactions

• The transactions involve the company and its CFO, which are considered related party dealings, but are standard for executive compensation.

Stakeholder Impact

• Shareholders: The grant of new RSUs to the CFO aligns management's long-term interests with shareholder value creation. The tax-related disposition is a minor, routine event.

Next Steps

• Future vesting of 21,701 RSUs, with one-third vesting annually starting February 20, 2027.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and new grants). It does not contain information that would fundamentally alter the investment thesis for Zimmer Biomet Holdings, Inc. The transactions are expected and reflect standard corporate governance and incentive structures. Therefore, a "hold" recommendation is appropriate as there's no new material information to warrant a change in existing positions based solely on this filing.

Keywords

ZBH, Zimmer Biomet, Suketu Upadhyay, CFO, Form 4, insider trading, restricted stock units, RSU, equity compensation, stock transactions